The sampling time post-symptom onset, vaccination or TMA test was indicated after sample ID. including DENV Citicoline sodium and ZIKV, DENV and YFV, and DENV, ZIKV and YFV. When screening 50 samples from your Philippines, we detected DENV, ZIKV, and DENV and ZIKV infections with a ZIKV seroprevalence rate of 10%, which was consistent with reports of low-level blood circulation of INHBB ZIKV in Asia. Together, these findings suggest that anti-prM antibody is usually a flavivirus serocomplex-specific marker and can be employed to delineate four flavivirus infections/exposure in regions where multiple flaviviruses co-circulate. KEYWORDS: Yellow fever computer virus, flavivirus, antibody, premembrane protein, serosurveillance Introduction In the genus of the family Flaviviridae, there are several mosquito-borne viruses causing significant diseases in humans; including the four serotypes of dengue computer virus (DENV) in the DENV serocomplex, West Nile computer virus (WNV) and Japanese encephalitis computer virus (JEV) in the JEV serocomplex, Zika computer virus (ZIKV), and yellow fever computer virus (YFV) as a single member [1]. The four serotypes of DENV (DENV1-DENV4) continue to be a global public health threat in tropical and subtropical regions [2-4]. It has been estimated that approximately 390 million DENV infections occur annually worldwide [2-4]. Most DENV infections are inapparent or subclinical with about 25% leading to clinical disease including dengue, dengue with warning signs, and severe dengue [2-4]. Of the DENV vaccine candidates that have completed different phases of clinical trials, Dengvaxia, a chimeric yellow fever-dengue tetravalent vaccine, was the first DENV vaccine licenced [5]. As DENV-seronegative children receiving Dengvaxia were reported to have a higher risk for hospitalization and severe dengue during subsequent DENV contamination, Dengvaxia was recommended for DENV-seropositive individuals aged 9C45 years [5-7]. Pre-vaccination screening strategies using assays with high sensitivity and specificity have been proposed, highlighting the need for reliable serological assessments to determine DENV serostatus in flavivirus-endemic regions [8]. Three additional flaviviruses, YFV, WNV, and ZIKV were also included in this research. In sub-Saharan Africa and tropical America, YFV is usually endemic with an estimate of 200,000 severe cases and up to 60,000 deaths per year [9,10]. The recent outbreaks in Angola and the Democratic Republic of the Congo, followed by the outbreaks in Brazil and Nigeria, suggest that YFV has expanded to new areas to impact large populations in South America and Africa [9,10]. First isolated in Uganda in 1937, WNV caused human cases and outbreaks in Africa and Europe; since 1999 WNV has spread throughout the continental US and to Canada and Mexico [1,11]. The reports of increased incidence in the geographic distribution of WNV and travel-related WNV cases posed new challenge of serosurveillance for flaviviruses [11,12]. ZIKV, first isolated in Uganda in 1947, was associated with relatively few human cases until the outbreaks on Yap Island in 2007 and French Polynesia in 2013?2014. The subsequent explosive spread in the Americas since 2015 has resulted in 800,000 suspected or confirmed cases [13,14]. The association of ZIKV with microcephaly and other birth defects, known as congenital Zika syndrome (CZS), has raised global public health concern [13-15]. Despite a decline in ZIKV transmission since late 2017, the spectre of its re-emergence and CZS in the endemic regions remains. Knowing the seroprevalence Citicoline sodium rates of flaviviruses is critical to our understanding of the epidemiology and transmission dynamics of flaviviruses and critical for the development of intervention strategies. In addition, information about DENV serostatus can be used to evaluate DENV vaccine efficacy and determine if an individual would benefit from Dengvaxia and/or other vaccine candidates. Due to the presence of mosquito vectors in these regions, there is considerable geographic overlap in the distribution of different flaviviruses, such as DENV, JEV and ZIKV in Southeast Asia; DENV, YFV and ZIKV in South America; and DENV, YFV, WNV and ZIKV in sub-Saharan Africa. Our knowledge about the effects of prior immunity to one flavivirus on disease end result of contamination with another flavivirus in humans was primarily based on cohort studies. It has been reported that preexisting JEV neutralizing antibodies increased symptomatic DENV contamination in Thailand [16]. Since the ZIKV outbreak during 2015?2017, two studies reported that prior DENV contamination was associated with Citicoline sodium reduced risk of symptomatic ZIKV contamination [17,18]. Another study showed that one prior ZIKV contamination or one prior DENV followed by one ZIKV contamination increased the.